CellCarta and Waters form a flow-cytometry companion-diagnostics partnership

CellCarta announced a strategic partnership with Waters on 5 October 2026 to jointly pursue companion-diagnostic and next-generation flow-cytometry opportunities with pharmaceutical and biotechnology sponsors. The collaboration initially emphasizes flow-cytometry programs. Waters contributes instrumentation, reagents, standardized panels, assay-development and software capabilities; CellCarta contributes biomarker development, clinical-trial testing, validation, regulatory/logistics support and deployment through its global CDx laboratory network.

The companies also identify CellCarta's Jining, China laboratory and existing alignment with Waters flow platforms as a practical foundation for multinational programs that include China.

CFCM explainer

Biomarker strategy → flow assay development → analytical/clinical validation → multicentre trial deployment → regulatory submission → possible commercial CDx.

Source/credit: CFCM pathway schematic based on the CellCarta corporate announcement, checked 6 October 2026. Alt text: companion-diagnostic development path from biomarker strategy through validation and global deployment to regulatory submission.

This is a strategic framework, not evidence that a specific companion diagnostic has completed validation or obtained marketing authorization. Claims about reducing complexity or improving global program continuity remain partnership objectives until demonstrated in specific programs.

Clinical flow cytometry is moving closer to formal companion-diagnostic development. The challenge is not only building a high-parameter panel, but locking and transferring the assay, controlling instruments and reagents, generating analytical and clinical evidence, and preserving performance across sites and jurisdictions.